In the late 1990s,
VistaGen Therapeutics’ founders established the company to make their dreams a
reality. The founders wanted to create human cell-based biological assay
systems that provide reliable insight into the healing and harmful effects of
new drug candidates long before they are ever tested in humans and, now,
next-generation biological assays can provide the type and quality of valuable
pre-clinical human data that will increase the possibility of choosing safer,
more effective therapeutics for clinical development.
VistaGen’s drug
rescue pursuits combine its human pluripotent stem cell technology platform,
Human Clinical Trials in a Test Tube™, with contemporary curative chemistry. By
doing so, the company is able to produce newer, safer chemical variants (drug
rescue variants) of once-promising small molecule drug candidates that were
halted in development by the U.S. National Institutes of Health, pharmaceutical
companies, or university laboratories because of heart or liver toxicity or
metabolism issues. VistaGen uses its stem cell technology to create early
predictions of how humans will eventually respond to the new drug candidates
before they are ever tested in humans, bringing human biology to the start of
the drug development process. Specifically, VistaGen applies its stem cell
technology to drug rescue, predictive toxicology, and drug metabolism
screening.
In the fifteen years
since the California-based biotechnology company was founded, VistaGen has
designed and developed CardioSafe 3D™, a high throughput, human heart
cell-based bioassay. Recently, the company reported significant developments
demonstrating that CardioSafe 3D is a clinically predictive system for the
preclinical cardiac safety screening of anti-cancer drug candidates, including
small molecule kinase inhibitors (KI), a new category of drugs that has
transformed cancer therapy due to its increased target cell efficacy and
reduced systemic toxicity when compared to classic cancer drugs.
The company is also
developing and validating LiverSafe 3D™, a novel, three-dimensional in-vitro
bioassay system for evaluating liver toxicity and drug metabolism issues.
VistaGen also has a
small molecule drug candidate in development: AV-101, an orally available small
molecule. AV-101 has completed Phase 1 development for the treatment of
neurological diseases and disorders, including neuropathic pain, a serious and
chronic condition that causes pain after an injury or disease of the peripheral
or central nervous system and that affects millions of people worldwide.
For more
information, visit www.vistagen.com.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment